Final Thoughts on Effective Therapy and Financial Toxicity
Experts in cancer management share their final thoughts on effective treatment and individualized care vs financial toxicity.
Innovation of Therapies vs Disruptive Pricing
A panel of experts debate the cost of innovation vs disruptive pricing of therapy.
Mitigating Strategies Appropriate for EGFR Therapy and Financial Toxicity
Jack West, MD, and Gilberto Lopes, MD, share their thoughts on mitigating strategies of therapy associated with financial toxicity.
Significance of PD-L1/PD-1 Testing in NSCLC
A panel of experts in cancer treatment review the need for PD-1/PD-L1 testing for immunotherapy.
Pharmacoeconomic Considerations for Immunotherapy
Gilberto Lopes, MD, Jack West, MD, and Mark Socinski, MD, provide their insight on the pharmacoeconomic considerations for immunotherapy.
Impact of Immunotherapy on Standard of Care for NSCLC and GI Cancers
Experts in cancer care management review PD-1/PD-L1 immunotherapy for patients with NSCLC and GI cancers.
Place for EGFR Agents and Comparison of Costs
A panel of experts discuss treatment options based on efficacy and out-of-pocket cost for patients.
Dr. Lopes on the KEYNOTE-042 Results of Frontline Pembrolizumab in NSCLC
Gilberto Lopes, MD, a medical oncologist at the Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses findings from the KEYNOTE-042 trial of frontline pembrolizumab (Keytruda) as a treatment for patients with squamous and nonsquamous non–small cell lung cancer in an interview with OncLive during the 2018 ASCO Annual Meeting.
Continued ADC Development in NSCLC Necessitates Improved Knowledge of Mechanisms and Biomarker Optimization
Neoadjuvant vs Perioperative Immune Checkpoint Blockade in Resectable NSCLC: How Do We Choose?
EGFR TKI–Based Combinations May Revolutionize Frontline EGFR+ NSCLC Management
Dr Olazagasti on a Case-Based Discussion of ALK-Mutated NSCLC Treatment
2 Commerce Drive Cranbury, NJ 08512